Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 261

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 19
Chunk 261
---
 2023, 239 common shares with a fair value of $ 27,965 were issued to consultants and 1,494 common shares with a fair value of $ 110,000 were issued to providers of investor services ...  

  (v)      On June 1, 2023, 245 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $ 48,194 at the time of issuance.  

  (vi)      On July 10, 2023, 597 common shares with a fair value of $ 10,000 were issued to providers of investor services in respect of services.  

  (vii)      On August 28, 2023, 585 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $ 65,143 at the time of issuance and 44 common shares with a fair...  

  (viii)      On September 18, 2023, the Company completed an underwritten public offering of 225,833 common shares at a price to the public of $ 9.00 per share and pre-funded warrants to purchase 24,167 com...  

  (ix)      During the period between October 17, 2023 and October 20, 2023, 784,584 April 2023 Warrants with a fair value of $ 574,040 were exercised into 119,433 common shares.  

F-26

CLEARMIND
MEDICINE INC.

Notes to
the Consolidated Financial Statements

(Expressed
in United States Dollars)

  Share                

  Share transactions during         
  the year ended October 31, 2022:  
 ────────────────────────────────────

  (i)      On November 26, 2021, the Company issued 44 common shares with a fair value of $ 21,100 to the Chief Science Officer (“ CSO”) of the Company.  

  (ii)      On February 14, 2022, the Company issued 45 common shares with a fair value of $ 17,584 to the CSO.  

  (iii)      On February 14, 2022, the Company completed a share purchase agreement with Xylo, whereby the Company issued a total of 2,208 units to Xylo in consideration for $ 750,000 (“ Cash